Grifols, S.A.
NASDAQ:GRFSDrug Manufacturers - General
+$0.03 today
- Market cap
- $7.17B
- Beta
- 1.17
- P/E (TTM)
- 14.7
- EPS (TTM)
- $0.61
- Dividend yield
- 1.67%
Volume 0.59M
Average 0.69M
GRFS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Grifols, S.A.NASDAQ: GRFS
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development dips below year-ago levels
Q2 FY2026 research & development of €86M fell 10.6% year over year, behind the +3.8% change in trailing-twelve-month research & development. Sequentially, it fell 6.0% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.
Context
- Research & development amounted to 5.0% of revenue in FY2025, down 0.4 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -10.6% toward the trailing-twelve-month pace of +3.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
EUR · from the income statement
- Latest · FY2025
- 358.28M EUR
- Year-over-year change
- -6.7%
- 4-year CAGR
- +0.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 358.28M | -6.7% |
| FY2024 | 2024-12-31 | 384.04M | -2.8% |
| FY2023 | 2023-12-31 | 395.28M | +9.5% |
| FY2022 | 2022-12-31 | 361.14M | +1.8% |
| FY2021 | 2021-12-31 | 354.88M | — |
Research & Development vs competitors
How GRFS compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +3.8% is the 4th highest of 9, against a peer median of -3.7%.
- Research & development amounts to 5.5% of revenue for GRFS, versus a peer median of 6.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $3.28B USD | +11.3% | +1.2% | 6.8% | |
| LTM Sep 2026 | $1.07B USD | -15.3% | -7.2% | 5.3% | |
| LTM Jun 2026 | €409.96M EUR | +3.8% | -0.3% | 5.5% | |
| LTM Jun 2026 | $261.1M USD | -14.3% | +0.0% | 10.1% | |
| LTM Mar 2026 | $177.9M USD | -16.4% | -0.3% | 6.7% | |
| LTM Sep 2026 | $96.87M USD | -3.0% | +0.8% | 7.9% | |
| LTM Jun 2026 | $59.46M USD | -4.4% | +0.6% | 4.4% | |
| LTM Jun 2026 | $21.15M USD | +13.2% | +8.3% | 10.1% | |
| LTM Jun 2026 | $11.52M USD | +332.9% | +9.6% | 2.2% | |
| Peer median (excluding GRFS) | — | -3.7% | +0.7% | 6.7% | |
Competitors are the stored peer set for GRFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.93B | 6.06B | 6.59B | 7.21B | 7.23B |
| Cost of Revenue | 2.97B | 3.85B | 4.11B | 4.42B | 4.65B |
| Gross Profit | 1.96B | 2.21B | 2.48B | 2.79B | 2.58B |
| Gross Margin | 39.8% | 36.5% | 37.7% | 38.7% | 35.7% |
| Research & Development | 354.88M | 361.14M | 395.28M | 384.04M | 358.28M |
| Selling, General & Admin | 1.06B | 1.11B | 1.27B | 1.14B | 1.02B |
| Operating Expenses | 1.37B | 1.43B | 1.7B | 1.6B | 1.39B |
| Depreciation & Amortization | 359.77M | 410.98M | 446.42M | 437.9M | 432.24M |
| EBITDA | 944.03M | 1.19B | 1.17B | 1.48B | 1.62B |
| EBITDA Margin | 19.1% | 19.7% | 17.7% | 20.6% | 22.5% |
| Operating Income | 595.06M | 782.44M | 782.32M | 1.19B | 1.19B |
| Operating Margin | 12.1% | 12.9% | 11.9% | 16.5% | 16.4% |
| Interest Income | 11.55M | 33.86M | 62.43M | 48.05M | 32.66M |
| Interest Expense | 233.81M | 444.54M | 516.06M | 773.16M | 600.33M |
| Other Income / Expenses | (244.61M) | (444.42M) | (575.3M) | (748.02M) | (596.49M) |
| Income Before Tax | 350.45M | 338.01M | 207.02M | 444M | 590.73M |
| Pre-Tax Margin | 7.1% | 5.6% | 3.1% | 6.2% | 8.2% |
| Income Tax Expense | 85.13M | 90.11M | 43.35M | 231.19M | 110.46M |
| Net Income | 188.73M | 185.04M | 42.32M | 156.92M | 386.13M |
| Net Margin | 3.8% | 3.1% | 0.6% | 2.2% | 5.3% |
| EPS (Basic) | 0.27 | 0.31 | 0.09 | 0.23 | 0.57 |
| EPS (Diluted) | 0.27 | 0.31 | 0.09 | 0.23 | 0.57 |
| Weighted Avg Shares | 681.56M | 679.81M | 679.76M | 680.02M | 680.58M |
| Weighted Avg Shares (Diluted) | 681.56M | 679.81M | 679.76M | 680.02M | 680.58M |
Grifols, S.A.
NASDAQ:GRFS
Intrinsic Alpha fair value
Locked
Current Price
$8.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.